{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T08:25:27Z","timestamp":1743409527844},"reference-count":51,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s305830","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T02:53:42Z","timestamp":1623293622000},"page":"493-502","source":"Crossref","is-referenced-by-count":3,"title":["US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Mike","family":"Dolph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyee","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"ref1","unstructured":"American Cancer Society. Cancer Facts & Figures; 2020. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html. Accessed January 23, 2020."},{"key":"ref2","unstructured":"Millennium Pharmaceuticals, Inc. Velcade\u00ae(bortezomib) injection [Prescribing Information]. Millennium Pharmaceuticals, Inc; 2019."},{"key":"ref3","unstructured":"National Comprehensive Cancer Network. NCCN\u00ae clinical practice guidelines in oncology (NCCN guidelines\u00ae) for antiemesis. (Version 2.2020). National Comprehensive Cancer Network (NCCN); 2020."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/BLCTT.S91251","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/phar.2267","volume":"39","author":"Hu","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref9","first-page":"3557","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood J Am Soc Hematol"},{"key":"ref10","first-page":"4745","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood J Am Soc Hematol"},{"key":"ref11","unstructured":"Karyopharm Therapeutics. XPOVIO (selinexor) [prescribing information]. XPOVIO (Selinexor). Available from: https:\/\/www.karyopharm.com\/wp-content\/uploads\/2019\/07\/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf. Accessed May 26, 2021."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"ref13","unstructured":"Sanchez L, Leleu X, Beaumont J, et al. Peripheral neuropathy symptoms, pain and functioning in relapsed or refractory multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone In: 62nd American Society of Hematology Annual Meeting and Exposition. 2020."},{"key":"ref14","unstructured":"National Institutes of Health. Surveillance, epidemiology, and end results program. multiple myeloma incidence rates per 100,000, SEER 13."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.18553\/jmcp.2019.25.2.272","volume":"25","author":"Runyan","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.18553\/jmcp.2018.24.1.39","volume":"24","author":"Djatche","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/CEOR.S251070","volume":"12","author":"Bassali","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"Mauskopf","year":"2007","journal-title":"Value Health"},{"key":"ref22","unstructured":"The AMCP format for formulary submissions, version 3.1. A format for submission of clinical and economic evidence of pharmaceuticals in support of formulary consideration. December 2012."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2017.1361035","volume":"59","author":"MacEwan","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref24","unstructured":"United Stated Bureau of Labor Statistics. Disease based price index neoplasm diseases. Available from: https:\/\/www.bls.gov\/pir\/diseasehome.htm. Accessed May 14, 2021."},{"key":"ref25","unstructured":"Kaiser Family Foundation. Medicare beneficiaries as a percent of total population. Available from: https:\/\/www.kff.org\/medicare\/state-indicator\/medicare-beneficiaries-as-of-total-pop\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Accessed May 14, 2021"},{"key":"ref26","unstructured":"AnalySource Drug Pricing Resource, 2020. Available from: https:\/\/www.analysource.com. Accessed January 2020."},{"key":"ref27","volume-title":"Budget-Impact Analysis of Health Care Interventions","year":"2017"},{"key":"ref28","unstructured":"Janssen Pharmaceutical Companies. DARZALEX (daratumumab) [prescribing information]. U.S. Food and Drug Administration website. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761036s013lbl.pdf. Accessed March 2019."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"haematologica"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1038\/bcj.2017.31","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0501-4","volume":"10","author":"Hou","year":"2017","journal-title":"J Hematol Oncol"},{"key":"ref36","unstructured":"Karyopharm Therapeutics, Inc. Selinexor brand impact multiple myeloma treatment topline report. Internal data on file. 2020."},{"key":"ref37","unstructured":"Karyopharm Therapeutics Inc. Clinical study report KCP-330-023. 2020."},{"key":"ref38","unstructured":"US Department of Health and Human Services. Agency for healthcare research and quality. HCUPnet. Healthcare Cost and Utilization Project; 2017."},{"key":"ref39","volume-title":"2017 HCPCS Level II Professional Edition-E-Book","year":"2017"},{"key":"ref40","unstructured":"US Census Bureau Population Division. Annual estimates of the resident population for selected age groups by sex for the United States: April 1, 2010 to July 1, 2019 (NC-EST2019-AGESEX). 2019."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Shao C, Monberg M, Cao X, Zhou W, Zhong Y, Marinello P. Real-world treatment patterns, health care utilization, and costs among relapsed\/refractory multiple myeloma (rrMM) patients. Washington, DC: American Society of Hematology; 2016.","DOI":"10.1182\/blood.V128.22.3555.3555"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.18553\/jmcp.2019.25.4.449","volume":"25","author":"Hollmann","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.18553\/jmcp.2017.23.10-a.s1","volume":"23","author":"Hollmann","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Potluri R, Bhandari H, Ranjan S, Chen C. Budget impact analysis of introducing elotuzumab in combination with lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma: a US payer perspective. Washington, DC: American Society of Hematology; 2016.","DOI":"10.1182\/blood.V128.22.2363.2363"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1634\/theoncologist.2018-0724","volume":"24","author":"Chari","year":"2019","journal-title":"Oncologist"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2040620719839025","DOI":"10.1177\/2040620719839025","volume":"10","author":"Song","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref49","author":"Kumar","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"v155","DOI":"10.1093\/annonc\/mdq178","volume":"21","author":"Harousseau","year":"2010","journal-title":"Ann Oncol"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Patel K, Parker T, Mengyang D, Bar N, Huntington S, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone (XVd) versus twice-weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma. 2020.","DOI":"10.1182\/blood-2020-141972"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=70398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=70398","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T02:53:55Z","timestamp":1623293635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/us-budget-impact-model-for-selinexor-bortezomib-and-dexamethasone-for--peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":51,"URL":"https:\/\/doi.org\/10.2147\/ceor.s305830","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}